Melissa Palmer

Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

Retrieved on: 
Friday, May 21, 2021
Medical specialties, Hepatitis, Anatomy, Clinical medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Liver disease, Melissa Palmer, Aramchol

b'WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET.\nThe fireside chat will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days.\nMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.

Key Points: 
  • b'WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET.\nThe fireside chat will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days.\nMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
  • Madrigal\xe2\x80\x99s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-\xce\xb2 selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.
  • For more information, visit www.madrigalpharma.com .\n'

Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET

Retrieved on: 
Tuesday, May 18, 2021
Medical specialties, Hepatitis, Anatomy, Clinical medicine, Steatohepatitis, Fatty liver disease, Non-alcoholic fatty liver disease, Liver disease, Melissa Palmer, Aramchol

b'WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will present at the RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET.\nThe presentation will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days.\nMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.

Key Points: 
  • b'WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will present at the RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET.\nThe presentation will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days.\nMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
  • Madrigal\xe2\x80\x99s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-\xce\xb2 selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.
  • For more information, visit www.madrigalpharma.com .\n'

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

Retrieved on: 
Thursday, February 25, 2021
Melissa Palmer, National Medical Products Administration, Gannex, Nash Motors, FASN, National Music Publishers Association, Cars, Automotive industry, China

The U.S. IND approval enables the Company to initiate the clinical trials in the U.S., the biggest NASH market in the world.

Key Points: 
  • The U.S. IND approval enables the Company to initiate the clinical trials in the U.S., the biggest NASH market in the world.
  • In May 2020, the first IND of ASC41 for NASH indication was approved by China's National Medical Products Administration(NMPA).
  • (Details referring to press release: https://www.ascletis.com/news_detail/175/id/46,2.html )
    Melissa Palmer, MD, Chief Medical Officer of Gannex said, "ASC41 is now the second NASH program we moved into the global development, as Gannex received IND approval and Fast Track Designation for ASC42, an FXR agonist less than 5 months ago.
  • Gannex has an aggressive pipeline development program for NASH with three different targets, FASN, THR- and FXR, and is progressing at full speed with two global development programs and one China focused program. "

Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Liver, Hepatology, Hepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, American Physiological Society, American Association for the Study of Liver Diseases, American Journal of Physiology, Physiology, Melissa Palmer

The study titled "Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization" was published in the American Journal of Physiology - Gastrointestinal and Liver Physiology, a journal of the American Physiological Society.

Key Points: 
  • The study titled "Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization" was published in the American Journal of Physiology - Gastrointestinal and Liver Physiology, a journal of the American Physiological Society.
  • Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and management of NAFLD/NASH disease.
  • There continues to be a concerted effort to accelerate the translation of innovative technologies to clinical studies and patient management.
  • The study is available at the American Journal of Physiology - Gastrointestinal and Liver Physiology website.

Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Liver, Hepatology, Hepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, American Physiological Society, American Association for the Study of Liver Diseases, American Journal of Physiology, Physiology, Melissa Palmer

The study titled "Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization" was published in the American Journal of Physiology - Gastrointestinal and Liver Physiology, a journal of the American Physiological Society.

Key Points: 
  • The study titled "Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization" was published in the American Journal of Physiology - Gastrointestinal and Liver Physiology, a journal of the American Physiological Society.
  • Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and management of NAFLD/NASH disease.
  • There continues to be a concerted effort to accelerate the translation of innovative technologies to clinical studies and patient management.
  • The study is available at the American Journal of Physiology - Gastrointestinal and Liver Physiology website.

Global Liver Institute Announces First Annual Rare Liver Diseases Month

Retrieved on: 
Monday, February 1, 2021
Medical specialties, Hepatitis, Clinical medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Alcoholic liver disease, Liver disease, Liver, Alcoholic hepatitis, Melissa Palmer, Foundation for Liver Research

Washington, DC, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), in their mission to improve the lives of individuals and families impacted by liver disease, has announced February 2021 as the first annual Rare Liver Diseases Month.

Key Points: 
  • Washington, DC, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), in their mission to improve the lives of individuals and families impacted by liver disease, has announced February 2021 as the first annual Rare Liver Diseases Month.
  • There are over 100 liver diseases, yet most liver diseases are often overshadowed by more common liver diseases such as alcoholic hepatitis, viral hepatitis, and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) due to their prevalence.
  • With Rare Liver Diseases Month and the #RareAware campaign, GLI aims to shine a light on these terrible diseases, raising awareness, and illuminating the need for policies and research that support rare liver patients.
  • In addition, in honor of Rare Liver Diseases Month, GLIs weekly online virtual event, GLI LIVE, hosted by Mrs. Cryer, airing live on Facebook, YouTube, and Periscope every Wednesday at 12pm EST, will focus on rare liver diseases.

Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”

Retrieved on: 
Thursday, January 28, 2021
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Liver, Hepatitis, Non-alcoholic fatty liver disease, Anatomy, Fatty liver disease, Liver disease, Nash, Bile acids, Melissa Palmer, Steatohepatitis

Can-Fites drug candidate Namodenoson completed a successful Phase II study in the treatment of non-alcoholic fatty liver disease (NAFLD)/NASH which met its endpoints.

Key Points: 
  • Can-Fites drug candidate Namodenoson completed a successful Phase II study in the treatment of non-alcoholic fatty liver disease (NAFLD)/NASH which met its endpoints.
  • The Company is currently preparing a Phase IIb study for Namodenoson in the treatment of NASH, the protocol for which has been designed by Dr. Harrison and other KOLs.
  • Dr. Harrison went on to indicate that future trials of Namodenoson in the treatment of NASH would target the population at greatest risk, those with some degree of fibrosis.
  • Dr. Harrison is Medical Director of Pinnacle Clinical Research, a gastroenterologist, and hepatologist specializing in metabolic liver disease.

Boston Medical Center Receives Support from Gilead Sciences to Improve Care for High-Risk Patients Living with Non-Alcoholic Fatty Liver Disease

Retrieved on: 
Wednesday, January 6, 2021
Medical specialties, Hepatitis, Anatomy, Non-alcoholic fatty liver disease, Fatty liver disease, Boston Medical Center, Clinical medicine, Steatohepatitis, Melissa Palmer

Long, an internationally recognized leader in NASH-research, will lead a multidisciplinary team of scientists in an effort to improve care for patients living with nonalcoholic fatty liver disease (NAFLD).

Key Points: 
  • Long, an internationally recognized leader in NASH-research, will lead a multidisciplinary team of scientists in an effort to improve care for patients living with nonalcoholic fatty liver disease (NAFLD).
  • Utilizing this grant from Gilead, our team will focus on better identifying and improving the standard of care for millions of patients suffering from fatty liver disease."
  • Boston Medical Center (BMC) is a private, not-for-profit, 514-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine.
  • Boston Medical Center and Boston University School of Medicine are partners in Boston HealthNet 12 community health centers focused on providing exceptional health care to residents of Boston.